Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 401-990-0 | CAS number: 106990-43-6 CHIMASSORB 119; LOWILITE 19
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Albino rats were treated with the substance for 90-days, administered in the diet.
Doses (male): 0, 9.7, 47.9, 201 and 826 mg/kg bw/day
Doses (female): 50.4, 210 and 817 mg/kg bw/day
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- other: not available
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1987
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Guideline not available
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Albino rat
- Sex:
- male/female
- Route of administration:
- oral: unspecified
- Details on oral exposure:
- Method of administration: diet
- Duration of treatment / exposure:
- Test duration: 90 days
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
Male: 10 animals at 9.7 mg/kg bw/day
Male: 10 animals at 47.9 mg/kg bw/day
Male: 10 animals at 201 mg/kg bw/day
Male: 10 animals at 826 mg/kg bw/day
Female: 10 animals at 0 mg/kg bw/day
Female: 10 animals at 9.92 mg/kg bw/day
Female: 10 animals at 50.4 mg/kg bw/day
Female: 10 animals at 210 mg/kg bw/day
Female: 10 animals at 817 mg/kg bw/day - Details on results:
- Clinical observation:
Dose-related reduction of mean body weight and food consumption at 12000 and 3000 ppm.
Water cosumption decreases at 12000 ppm.
Laboratory findings:
At 12000 ppm hypocromic microcytic anemia. At 12000, 3000 and 800 ppm dose-related leucocytosis with neutrophilia and relative lymphopenia. At 12000 ppm decrease in plasma glucose, cholesterol and plasma protein; dose-related decrease in plasma albumin at 12000 and 3000 ppm.
At 12000 ppm increases in plasma electrolytes, ASAT and alcaline phosphatase; ASAT increased in females at 3000 and 800 ppm too. Bilirubinuria at 12000 ppm.
Effects in organs:
Increase of liver relative weight in females at 12000 ppm and of spleen relative weight in females at 3000 and 12000 ppm. Enlarges mesenteric lymphonodes at 800, 3000 and 12000 ppm. Two/20 rats at 12000 ppm had mottled liver.
Marked, widespread presence of foam macrophages, expecially in the mucosa of small intestine and in the mesenteric lymphnodes. The change was evident form 150 ppm exposure upwards, and its intesity was dose-related.
At 800, 3000 and 12000 ppm necrotizing, inflammatory and cystic changes in mesenteric lymph nodes, peritoneal inflammation, and inflammatory infiltrates in liver (1/20 at 800 ppm) were also present. - Dose descriptor:
- NOEL
- Effect level:
- < 9.7 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day
- Critical effects observed:
- not specified
- Conclusions:
- The substance is not classified.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 9.7 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The Repeated dose toxicity study (90-days in rat) was submitted more than 12 years ago. It is not known if it was performed under GLP conditions.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Dose at which no toxic effects were observed: 9.7 mg/kg/day in males and 9.92 mg/kg/day in females
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The study with longest duration (90-days) and lowest NOAEL was chosen as key study.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
Study scientifically unjustified.
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
Study scientifically unjustified.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
Study scientifically unjustified.
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
Study scientifically unjustified.
Justification for classification or non-classification
The substance N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine does not required classification for repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.